Lung cancer brain metastasis study halted after just 3 patients
NCT ID NCT04964960
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study aimed to see if adding the drug pembrolizumab to chemotherapy could help control lung cancer that has spread to the brain without causing new symptoms. It was designed for people with untreated, asymptomatic brain metastases and no specific genetic mutations. However, the study was terminated early after enrolling only 3 participants, so no meaningful conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky, Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.